Advances in Biomarker Research for Pancreatic Cancer

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2012 Mar 1

PMID 22372502

Citations 36

Authors

Kruttika Bhat

Fengfei Wang

Qingyong Ma

Qinyu Li

Sanku Mallik

Tze-Chen Hsieh

Erxi Wu

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical. Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.

Citing Articles

Differential extracellular vesicle concentration and their biomarker expression of integrin α/β, EpCAM, and glypican-1 in pancreatic cancer models.

Jacobson R, Ha S, Tani S, Ghosh S, Jarajapu Y, Brand R Sci Rep. 2024; 14(1):14273.

PMID: 38902362 PMC: 11189911. DOI: 10.1038/s41598-024-65209-8.

Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products.

Park M Int J Mol Sci. 2023; 24(21).

PMID: 37958889 PMC: 10648679. DOI: 10.3390/ijms242115906.

The Chi-Square Test of Distance Correlation.

Shen C, Panda S, Vogelstein J J Comput Graph Stat. 2022; 31(1):254-262.

PMID: 35707063 PMC: 9191842. DOI: 10.1080/10618600.2021.1938585.

Current State of "Omics" Biomarkers in Pancreatic Cancer.

Turanli B, Yildirim E, Gulfidan G, Arga K, Sinha R J Pers Med. 2021; 11(2).

PMID: 33672926 PMC: 7918884. DOI: 10.3390/jpm11020127.

Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.

Fahrmann J, Schmidt C, Mao X, Irajizad E, Loftus M, Zhang J Gastroenterology. 2020; 160(4):1373-1383.e6.

PMID: 33333055 PMC: 8783758. DOI: 10.1053/j.gastro.2020.11.052.

References

Sergeant G, Vankelecom H, Gremeaux L, Topal B . Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat Rev Clin Oncol. 2009; 6(10):580-6. DOI: 10.1038/nrclinonc.2009.127. View

Latchford A, Greenhalf W, Vitone L, Neoptolemos J, Lancaster G, Phillips R . Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg. 2006; 93(12):1446-55. DOI: 10.1002/bjs.5609. View

Iodice S, Gandini S, Maisonneuve P, Lowenfels A . Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008; 393(4):535-45. DOI: 10.1007/s00423-007-0266-2. View

Chen R, Brentnall T, Pan S, Cooke K, White Moyes K, Lane Z . Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics. 2007; 6(8):1331-42. DOI: 10.1074/mcp.M700072-MCP200. View

Pizzi S, Azzoni C, Bottarelli L, Campanini N, DAdda T, Pasquali C . RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol. 2005; 206(4):409-16. DOI: 10.1002/path.1784. View

Iacobuzio-Donahue C, Maitra A, Olsen M, Lowe A, Van Heek N, Rosty C . Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003; 162(4):1151-62. PMC: 1851213. DOI: 10.1016/S0002-9440(10)63911-9. View

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Mulero-Navarro S, Esteller M . Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol. 2008; 68(1):1-11. DOI: 10.1016/j.critrevonc.2008.03.001. View

Wolpin B, Chan A, Hartge P, Chanock S, Kraft P, Hunter D . ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009; 101(6):424-31. PMC: 2657095. DOI: 10.1093/jnci/djp020. View

10.

Ghaneh P, Costello E, Neoptolemos J . Biology and management of pancreatic cancer. Postgrad Med J. 2008; 84(995):478-97. DOI: 10.1136/gut.2006.103333. View

11.

Jiang X, Tao H, Zou S . Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2004; 3(3):464-8. View

12.

Heinemann V . Gemcitabine: progress in the treatment of pancreatic cancer. Oncology. 2001; 60(1):8-18. DOI: 10.1159/000055290. View

13.

Iacobuzio-Donahue C, Fu B, Yachida S, Luo M, Abe H, Henderson C . DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27(11):1806-13. PMC: 2668706. DOI: 10.1200/JCO.2008.17.7188. View

14.

Tian F, Appert H, Myles J, Howard J . Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg. 1992; 215(4):350-5. PMC: 1242451. DOI: 10.1097/00000658-199204000-00008. View

15.

Kruger M, Moser M, Ussar S, Thievessen I, Luber C, Forner F . SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008; 134(2):353-64. DOI: 10.1016/j.cell.2008.05.033. View

16.

Karna E, Surazynski A, Orlowski K, Laszkiewicz J, Puchalski Z, Nawrat P . Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol. 2003; 83(5):239-45. PMC: 2517686. DOI: 10.1046/j.1365-2613.2002.00237.x. View

17.

Zhang Y, Li M, Wang H, Fisher W, Lin P, Yao Q . Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2008; 33(4):698-709. PMC: 2933040. DOI: 10.1007/s00268-008-9833-0. View

18.

Gao J, Zhu F, Lv S, Li Z, Ling Z, Gong Y . Identification of pancreatic juice proteins as biomarkers of pancreatic cancer. Oncol Rep. 2010; 23(6):1683-92. DOI: 10.3892/or_00000812. View

19.

Kong X, Du Y, Wang G, Gao J, Gong Y, Li L . Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2010; 56(2):602-9. DOI: 10.1007/s10620-010-1285-3. View

20.

Ghaneh P, Kawesha A, Evans J, Neoptolemos J . Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002; 9(1):1-11. DOI: 10.1007/s005340200000. View